|
HUE033894T2
(en)
*
|
2006-08-23 |
2018-01-29 |
Kudos Pharm Ltd |
2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
|
|
SI2125797T1
(sl)
*
|
2007-03-16 |
2014-03-31 |
Actelion Pharmaceuticals Ltd. |
Derivati amino-piridina kot agonisti receptorja s1p1/edg1
|
|
US20080234262A1
(en)
*
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
|
US9029411B2
(en)
|
2008-01-25 |
2015-05-12 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and uses thereof
|
|
KR101331341B1
(ko)
|
2008-05-23 |
2013-11-19 |
와이어쓰 엘엘씨 |
Ｐｉ３ 키나제 및 ｍｔｏｒ 억제제로서의 트리아진 화합물
|
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
|
EP2391619A1
(en)
*
|
2009-01-30 |
2011-12-07 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and their use as pi3k inhibitors
|
|
UY32470A
(es)
|
2009-03-05 |
2010-10-29 |
Boehringer Ingelheim Int |
Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
WO2011067356A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Polymorphs of a mek inhibitor
|
|
WO2011067348A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Mek inhibitor salts and solvates thereof
|
|
EP2992878A1
(en)
|
2010-02-03 |
2016-03-09 |
Signal Pharmaceuticals, LLC |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
GB201004200D0
(en)
*
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
WO2011120911A1
(en)
|
2010-03-30 |
2011-10-06 |
Novartis Ag |
Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
|
|
ES2689177T3
(es)
|
2010-04-13 |
2018-11-08 |
Novartis Ag |
Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
|
|
KR20130048293A
(ko)
|
2010-06-25 |
2013-05-09 |
노파르티스 아게 |
단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
|
|
US9062038B2
(en)
|
2010-08-11 |
2015-06-23 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US8759537B2
(en)
|
2010-08-20 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
|
|
US8586604B2
(en)
|
2010-08-20 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
Inhibitors of the microsomal prostaglandin E2 synthase-1
|
|
US8466186B2
(en)
|
2010-12-10 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
|
US8674113B2
(en)
|
2010-12-10 |
2014-03-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
|
US8486968B2
(en)
|
2010-12-10 |
2013-07-16 |
Boehringer Ingelheim International Gmbh |
Compounds
|
|
AU2012290056B2
(en)
|
2011-08-03 |
2015-03-19 |
Signal Pharmaceuticals, Llc |
Identification of gene expression profile as a predictive biomarker for LKB1 status
|
|
JP6026544B2
(ja)
|
2011-09-27 |
2016-11-16 |
ノバルティス アーゲー |
変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類
|
|
ES2694413T3
(es)
*
|
2011-12-02 |
2018-12-20 |
Signal Pharmaceuticals, Llc |
Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
JP6120311B2
(ja)
*
|
2013-02-12 |
2017-04-26 |
学校法人銀杏学園 |
ポリフェノール化合物
|
|
GEP201706699B
(en)
|
2013-03-14 |
2017-07-10 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
WO2014172432A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
|
SG11201508527VA
(en)
|
2013-04-17 |
2015-11-27 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
|
MX364101B
(es)
|
2013-04-17 |
2019-04-12 |
Signal Pharm Llc |
Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
|
|
EA030808B1
(ru)
|
2013-04-17 |
2018-09-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
|
|
HK1221174A1
(zh)
|
2013-04-17 |
2017-05-26 |
西格诺药品有限公司 |
用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
|
|
CA2909579A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
|
HK1221150A1
(zh)
|
2013-04-17 |
2017-05-26 |
西格诺药品有限公司 |
用二氢吡嗪并-吡嗪类对癌症的治疗
|
|
CA3143529A1
(en)
|
2013-05-29 |
2014-12-04 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
JP2017505787A
(ja)
*
|
2014-02-14 |
2017-02-23 |
ザ ユニバーシティ オブ ブリティッシュ コロンビア |
治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法
|
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
MY198676A
(en)
|
2017-06-22 |
2023-09-15 |
Celgene Corp |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
|
EP4161926A4
(en)
*
|
2020-06-03 |
2024-06-19 |
Yumanity Therapeutics, Inc. |
PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
|
|
WO2025012643A1
(en)
|
2023-07-11 |
2025-01-16 |
Tay Therapeutics Limited |
Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents
|